Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

AZD2816 Study Group, Maheshi N Ramasamy, Elizabeth J. Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne, Vincenzo Libri, Matthew Adam, Parvinder K Aley, Nuria Martinez-Alier, Alison Church, Brett Jepson, Mark Khan, Sam Matthews, G Todd Townsend, Johan Vekemans, Sagida Bibi, Phillip A Swanson, Teresa Lambe, Menelas N PangalosTonya Villafana, Andrew J Pollard, Justin A Green

Research output: Contribution to journal › Article › peer-review

22 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland'. Together they form a unique fingerprint.

Medicine & Life Sciences